<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36090973</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Immunologic phenotype of patients with long-COVID syndrome of 1-year duration.</ArticleTitle><Pagination><StartPage>920627</StartPage><MedlinePgn>920627</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">920627</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.920627</ELocationID><Abstract><AbstractText Label="BACKGROUND">The pathophysiology of long-COVID remains unknown, and information is particularly limited for symptoms of very long duration. We aimed to assess the serological, T-cell immune responses and ANA titers of patients with long-COVID-19 syndrome of 1-year duration.</AbstractText><AbstractText Label="METHODS">Prospective, longitudinal study of hospitalized COVID-19 patients followed-up for 12 months. Sequential blood samples and COVID-19 symptom questionnaires (CSQ) were obtained, and humoral and cellular immune responses, antinuclear antibodies (ANA) and inflammation biomarkers were analyzed.</AbstractText><AbstractText Label="RESULTS">Of 154 patients discharged from hospital, 72 non-vaccinated with available CSQ in all visits were included. Of them, 14 (19.4%) reported persistent symptoms both at 6-months and 12-months, mainly asthenia (15.3%), myalgia (13.9%), and difficulty concentrating/memory loss (13.9%). Symptomatic patients were more frequently women, smokers, showed higher WHO severity score, and a trend to higher ICU admission. In the adjusted analysis, long-COVID syndrome was associated with lower frequency of detectable neutralizing antibodies (adjusted hazard ratio [aHR] 0.98; 95% confidence interval [CI], 0.97-0.99) and lower SARS-CoV-2-S1/S2 titers (aHR [95%CI] 0.14 [0.03-0.65]). T-cell immune response measured with a SARS-CoV-2-interferon-&#x3b3; release assay was not different between groups. There was a higher frequency of positive ANA titers (&#x2265;160) in symptomatic patients (57.1% vs 29.3%, p=0.04), that was attenuated after adjustment aHR [95% CI] 3.37 [0.84-13.57], p=0.087. Levels of C-reactive protein and D-dimer were higher during follow-up in symptomatic patients, but with no differences at 12 months.</AbstractText><AbstractText Label="CONCLUSION">Patients with 1-year duration long-COVID-19 syndrome exhibit a distinct immunologic phenotype that includes a poorer SARS-CoV-2 antibody response, low-degree chronic inflammation that tends to mitigate, and autoimmunity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Garc&#xed;a-Abell&#xe1;n, Fern&#xe1;ndez, Padilla, Garc&#xed;a, Agull&#xf3;, Lozano, Ena, Garc&#xed;a-S&#xe1;nchez, Guti&#xe9;rrez and Masi&#xe1;.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garc&#xed;a-Abell&#xe1;n</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Medicine Department, Universidad Miguel Hern&#xe1;ndez, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padilla</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Medicine Department, Universidad Miguel Hern&#xe1;ndez, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>Jos&#xe9; Alberto</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agull&#xf3;</LastName><ForeName>Vanesa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lozano</LastName><ForeName>Valle</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ena</LastName><ForeName>Nuria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-S&#xe1;nchez</LastName><ForeName>Lidia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guti&#xe9;rrez</LastName><ForeName>F&#xe9;lix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Medicine Department, Universidad Miguel Hern&#xe1;ndez, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masi&#xe1;</LastName><ForeName>Mar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Medicine Department, Universidad Miguel Hern&#xe1;ndez, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">T-cell immune response</Keyword><Keyword MajorTopicYN="N">antibody response, antinuclear antibodies (ANA)</Keyword><Keyword MajorTopicYN="N">cellular immune response</Keyword><Keyword MajorTopicYN="N">humoral immune response</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">one year</Keyword><Keyword MajorTopicYN="N">post-COVID-19 syndrome</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>12</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36090973</ArticleId><ArticleId IdType="pmc">PMC9451924</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.920627</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ (2021) 372:136. doi:&#xa0;10.1136/bmj.n136</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. . Attributes and predictors of long COVID. Nat Med (2021) 27:626&#x2013;31. doi:&#xa0;10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. . More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep (2021) 11:16144. doi:&#xa0;10.1038/s41598-021-95565-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PloS Med (2021) 18:e1003773. doi:&#xa0;10.1371/journal.pmed.1003773</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet (2021) 397:220&#x2013;32. doi:&#xa0;10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellan M, Baricich A, Patrucco F, Zeppegno P, Gramaglia C, Balbo PE, et al. . Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19. Sci Rep (2021) 11:22666. doi:&#xa0;10.1038/s41598-021-01215-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-01215-4</ArticleId><ArticleId IdType="pmc">PMC8608998</ArticleId><ArticleId IdType="pubmed">34811387</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardo MDM, Foppiani A, Peretti GM, Mangiavini L, Battezzati A, Bertoli S, et al. . Long-term coronavirus disease 2019 complications in inpatients and outpatients: A one-year follow-up cohort study. Open Forum Infect Dis (2021) 8:ofab384. doi:&#xa0;10.1093/ofid/ofab384</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab384</ArticleId><ArticleId IdType="pmc">PMC8344801</ArticleId><ArticleId IdType="pubmed">34386546</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan FJ, Hope CM, Masavuli MG, Lynn MA, Mekonnen ZA, Yeow AEL, et al. . Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med (2022) 20:26. doi:&#xa0;10.1186/s12916-021-02228-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02228-6</ArticleId><ArticleId IdType="pmc">PMC8758383</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Files JK, Boppana S, Perez MD, Sarkar S, Lowman KE, Qin K, et al. . Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection. J Clin Invest (2021) 131:e140491. doi:&#xa0;10.1172/JCI140491</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI140491</ArticleId><ArticleId IdType="pmc">PMC7773371</ArticleId><ArticleId IdType="pubmed">33119547</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheon IS, Li C, Son YM, Goplen NP, Wu Y, Cassmann T, et al. . Immune signatures underlying post-acute COVID-19 lung sequelae. Sci Immunol (2021) 6:eabk1741. doi:&#xa0;10.1126/sciimmunol.abk1741</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abk1741</ArticleId><ArticleId IdType="pmc">PMC8763087</ArticleId><ArticleId IdType="pubmed">34591653</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J, Padilla S, Fern&#xe1;ndez-Gonz&#xe1;lez M, Garc&#xed;a JA, Agull&#xf3; V, Andreo M, et al. . Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study. J Clin Immunol (2021) 41:1490&#x2013;501. doi:&#xa0;10.1007/s10875-021-01083-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01083-7</ArticleId><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko N, Kuo HH, Boucau J, Farmer JR, Allard-Chamard H, Mahajan VS, et al. . Loss of bcl-6-Expressing T follicular helper cells and germinal centers in COVID-19. Cell (2020) 183:143&#x2013;57.e13. doi:&#xa0;10.1016/j.cell.2020.08.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.025</ArticleId><ArticleId IdType="pmc">PMC7437499</ArticleId><ArticleId IdType="pubmed">32877699</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, Zurbuchen Y, Taeschler P, Ballouz T, Menges D, Hasler S, et al. . Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun (2022) 13:446. doi:&#xa0;10.1038/s41467-021-27797-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27797-1</ArticleId><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura AD, da Costa HHM, Correa VA, de S Lima AK, Lindoso JAL, De Gaspari E, et al. . Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients. Sci Rep (2021) 11:17642. doi:&#xa0;10.1038/s41598-021-95045-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95045-z</ArticleId><ArticleId IdType="pmc">PMC8417219</ArticleId><ArticleId IdType="pubmed">34480056</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemi&#x144;ska I, W&#x119;glarczyk K, Surmiak M, Kurowska-Baran D, Sanak M, Siedlar M, et al. . Mild and asymptomatic COVID-19 convalescents present long-term endotype of immunosuppression associated with neutrophil subsets possessing regulatory functions. Front Immunol (2021) 12:748097. doi:&#xa0;10.3389/fimmu.2021.748097</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.748097</ArticleId><ArticleId IdType="pmc">PMC8511487</ArticleId><ArticleId IdType="pubmed">34659245</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy WJ, Longo DL. A possible role for anti-idiotype antibodies in SARS-CoV-2 infection and vaccination. N Engl J Med (2022) 386:394&#x2013;96. doi:&#xa0;10.1056/NEJMcibr2113694</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcibr2113694</ArticleId><ArticleId IdType="pubmed">34818473</ArticleId></ArticleIdList></Reference><Reference><Citation>Truong TT, Ryutov A, Pandey U, Yee R, Goldberg L, Bhojwani D, et al. . Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity. EBioMedicine (2021) 67:103355. doi:&#xa0;10.1101/2021.02.27.21252099</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.27.21252099</ArticleId><ArticleId IdType="pmc">PMC8072072</ArticleId><ArticleId IdType="pubmed">33915337</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuboi N, Asano K, Lauterbach M, Mayadas TN. Human neutrophil fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. Immunity (2008) 28:833&#x2013;46. doi:&#xa0;10.1016/j.immuni.2008.04.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2008.04.013</ArticleId><ArticleId IdType="pmc">PMC2577844</ArticleId><ArticleId IdType="pubmed">18538590</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. . New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun (2021) 12:5417. doi:&#xa0;10.1038/s41467-021-25509-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascolini S, Vannini A, Deleonardi G, Ciordinik M, Sensoli A, Carletti I, et al. . COVID-19 and immunological dysregulation: can autoantibodies be useful? Clin Transl Sci (2021) 14:502&#x2013;8. doi:&#xa0;10.1111/cts.12908</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12908</ArticleId><ArticleId IdType="pmc">PMC7536986</ArticleId><ArticleId IdType="pubmed">32989903</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. . Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin Infect Dis (2022) 74:1191&#x2013;8. doi:&#xa0;10.1093/cid/ciab611</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Thomas IJ, Munter SE, Deeks SG, Henrich TJ. Lack of antinuclear antibodies in convalescent COVID-19 patients with persistent symptoms. Clin Infect Dis (2022), 74:ciab890. doi:&#xa0;10.1093/cid/ciab890</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab890</ArticleId><ArticleId IdType="pmc">PMC9187313</ArticleId><ArticleId IdType="pubmed">34617982</ArticleId></ArticleIdList></Reference><Reference><Citation>Chepy A, Bourel L, Koether V, Launay D, Dubucquoi S, Sobanski V. Can antinuclear antibodies have a pathogenic role in systemic sclerosis? Front Immunol (2022) 13:930970. doi:&#xa0;10.3389/fimmu.2022.930970</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.930970</ArticleId><ArticleId IdType="pmc">PMC9274282</ArticleId><ArticleId IdType="pubmed">35837382</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol (2022) 23:210&#x2013;6. doi:&#xa0;10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kratzer B, Trapin D, Ettel P, Kormoczi U, Rottal A, Tuppy F, et al. . Immunological imprint of COVID-19 on human peripheral blood leukocyte populations. Allergy (2021) 76:751&#x2013;65. doi:&#xa0;10.1111/all.14647</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14647</ArticleId><ArticleId IdType="pmc">PMC7984452</ArticleId><ArticleId IdType="pubmed">33128792</ArticleId></ArticleIdList></Reference><Reference><Citation>Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci (2003) 100:9452&#x2013;7. doi:&#xa0;10.1073/pnas.1632807100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1632807100</ArticleId><ArticleId IdType="pmc">PMC170939</ArticleId><ArticleId IdType="pubmed">12878725</ArticleId></ArticleIdList></Reference><Reference><Citation>Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, et al. . Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity (2004) 21:357&#x2013;66. doi:&#xa0;10.1016/j.immuni.2004.06.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2004.06.020</ArticleId><ArticleId IdType="pubmed">15357947</ArticleId></ArticleIdList></Reference><Reference><Citation>Ausiello CM, Urbani F, la Sala A, Funaro A, Malavasi F. CD38 ligation induces discrete cytokine mRNA expression in human cultured lymphocytes. Eur J Immunol (1995) 25:1477&#x2013;80. doi:&#xa0;10.1002/eji.1830250554</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.1830250554</ArticleId><ArticleId IdType="pubmed">7774653</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong SWX, Fong SW, Young BE, Chan YH, Lee B, Amrun SN, et al. . Persistent symptoms and association with inflammatory cytokine signatures in recovered coronavirus disease 2019 patients. Open Forum Infect Dis (2021) 8:ofab156. doi:&#xa0;10.1093/ofid/ofab156</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab156</ArticleId><ArticleId IdType="pmc">PMC8083585</ArticleId><ArticleId IdType="pubmed">34095336</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>